Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
(2024 Nov 27)
N Engl J Med
Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O, PURPOSE 2 Study Team

Understanding the sources of efficacy dilution in a trial of a monthly dapivirine vaginal ring for HIV-1 prevention.
(2024 Nov 26)
Int J STD AIDS
Peebles K, Matrajt L, Baeten JM, Palanee-Phillips T, Brown ER, MTN-020/ASPIRE Study Team

Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex Human Immunodeficiency Virus Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1).
(2024 Nov 26)
Clin Infect Dis
Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, Mendes I, Guo Y, Arora P, Montezuma-Rusca JM, Sklar P, Baeten JM, Segal-Maurer S

Acceptability of six-monthly PrEP dispensing supported with interim HIV self-testing to simplify PrEP delivery in Kenya: findings from qualitative research.
(2024 Oct 24)
BMC Health Serv Res 24(1): 1281
Thuo N, Bardon AR, Mogere P, Kiptinness C, Casmir E, Wairimu N, Owidi E, Okello P, Mugo NR, Baeten JM, Ngure K, Ortblad KF

Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence.
(2024 Nov)
AIDS Behav 28(11): 3873-3882
Husnik MJ, Heffron R, Hughes JP, Richardson B, van der Straten A, Palanee-Phillips T, Soto-Torres L, Singh D, Mirembe BG, Livant E, Gaffoor Z, Mansoor LE, Siva SS, Dadabhai S, Kiweewa FM, Baeten JM, MTN-020/ASPIRE Study Team